ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint747,212 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical companyEpalingesHaya Therapeutics SA
Haya Therapeutics SA Logo
Verified· 3 sourcesTrust Score
Summary

About the company

Haya Therapeutics SA is a biotechnology company developing RNA-based therapeutics. Its regulatory-genome platform identifies disease-related non-coding RNAs and supports the development of antisense therapies, including for fibrotic, metabolic and age-related diseases.

AI-generated
Offering

Products & services

Industry:Pharmaceutical company
✓ Offered6
RNA-guided therapies
RNA-guided therapies built on causal biology to reverse disease-driving cell states and restore health; focused on programmable RNA medicines against disease causes.
Drug discovery and development of RNA medicines
A platform that translates regulatory genome insights into RNA-guided medicines; includes target identification, design of programmable RNA medicines, and early translation through clinical development.
Pipeline development for therapeutic programs
A portfolio of RNA medicines for areas of urgent medical need; includes cardiac, pulmonary, oncology and other discovery programs from identification to Phase 1.
Partnerships for drug discovery
Collaborating to reprogram disease faster; partnerships with biotech and pharma players to identify new targets and translate causal biology insights into therapies.
Discovery of regulatory genome targets
Identification of causal RNA-based drug targets from the regulatory genome; used for programs in obesity, metabolic diseases and other disease areas.
Preclinical and clinical development of oligonucleotide therapeutics
Advance disease-, tissue- and cell-specific lncRNA discoveries into novel oligonucleotides-based therapies; includes development candidates through IND and clinical Phase 1.
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

Haya Therapeutics SA

Trust & reputation

ranQ Trust Score of Haya Therapeutics SA: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 58% · As of November 2026

Without public customer reviews the score stays capped.

Haya Therapeutics SA has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Haya Therapeutics SA scores 81.6 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.75.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.82.07%
Haya Therapeutics SA scores 86.7 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).86.722%
Haya Therapeutics SA scores 63.6 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.97.14%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.30.04%
Qualifications+0.00

Haya Therapeutics SA reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 58%, so the score is backed by part of the criteria. As of November 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Press

Media

May 20, 2026Media
HAYA Therapeutics starts clinical trial for heart disease therapy
venturelab.swiss
May 8, 2025Media
HAYA Therapeutics banks $65 million Series A funding
startupticker.ch

Knowledge

No knowledge articles yet

Once Haya Therapeutics SA has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Haya Therapeutics SA in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Haya Therapeutics SA by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Haya Therapeutics SA to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Route de la Corniche 5 b
1066 Epalinges

At a glance

Legal form
Corporation
UID
CHE-187.646.914
Founded
2019 · 7 years
Last commercial register change
June 2, 2026
Employees
21 to 50
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
  • Full methodology

    Similar companies

    ST
    Synameta Therapeutics SARL
    Epalinges
    NB
    ND BioSciences SA
    Epalinges
    ES
    Exciva Switzerland SA
    Epalinges
    VS
    Vandria SA
    Epalinges
    LH
    Legacy Healthcare SA
    Epalinges
    BT
    Biodelphis Therapeutics SA
    Lausanne
    HS
    HemostOD SA
    St-Sulpice Vd
    SL
    S.P. Laboratories SA
    Pully